Vasomune Therapeutics, a leading biotechnology company developing therapeutics targeting vascular dysfunction and inflammation, announced that Douglas A. Hamilton has been appointed President and Chief Executive Officer of the company.
Advanced Code injection
Vasomune Therapeutics, a leading biotechnology company developing therapeutics targeting vascular dysfunction and inflammation, announced that Douglas A. Hamilton has been appointed President and Chief Executive Officer of the company.